Dashboard
Company has a low Debt to Equity ratio (avg) at times
Poor long term growth as Net Sales has grown by an annual rate of 3.61% and Operating profit at 2.86% over the last 5 years
Positive results in Jun 25
With ROE of 5.27%, it has a expensive valuation with a 2.40 Price to Book Value
High Institutional Holdings at 79.31%
Consistent Underperformance against the benchmark over the last 3 years
Total Returns (Price + Dividend) 
HealthStream, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
Is HealthStream, Inc. overvalued or undervalued?
As of 31 October 2025, the valuation grade for HealthStream, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 46, an EV to EBITDA of 12.29, and a PEG ratio of 6.67, which suggest that while the company is not undervalued, it is also not excessively priced compared to its peers. In comparison to its peers, HealthStream, Inc. has a P/E ratio of 40.95, which is lower than the significantly high P/E ratios of Enfusion, Inc. at 260.46 and Cerence, Inc. at 409.37, indicating a more reasonable valuation within the software products industry. However, the company has underperformed against the S&P 500 over multiple periods, with a year-to-date return of -18.14% compared to the S&P 500's 16.30%, which may reflect broader market trends or company-specific challenges....
Read More
HealthStream, Inc. Hits New 52-Week Low at $24.07
HealthStream, Inc. has reached a new 52-week low, reflecting a year-to-date decline while the S&P 500 has gained. The company, with a market cap of approximately USD 833 million, shows modest growth in net sales and operating profit, but has underperformed against broader market indices over the past three years.
Read MoreIs HealthStream, Inc. overvalued or undervalued?
As of 31 October 2025, the valuation grade for HealthStream, Inc. moved from expensive to fair. The company appears fairly valued based on its current metrics. Key ratios include a P/E ratio of 46, a Price to Book Value of 2.40, and an EV to EBITDA of 12.29, which suggest that while the company is not undervalued, it is also not excessively priced compared to its peers. In comparison to its peers, HealthStream's P/E ratio of 40.95 is significantly lower than Pagaya Technologies Ltd.'s 71.76, indicating a more attractive valuation despite the higher absolute P/E. Couchbase, Inc. shows a negative P/E, further emphasizing HealthStream's relative stability. Although return data is not available, the company's performance can be assessed against the S&P 500, reinforcing the notion that HealthStream is positioned fairly within its market context....
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 68 Schemes (36.7%)
Held by 91 Foreign Institutions (7.43%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 1.22% vs -0.94% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 25.58% vs -12.24% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 4.48% vs 4.61% in Dec 2023
YoY Growth in year ended Dec 2024 is 31.58% vs 25.62% in Dec 2023






